Clinical relevance of cleaved RAGE plasma levels as a biomarker of disease severity and functional outcome in aneurysmal subarachnoid hemorrhage

Yang, Dan; Dong, Xiao-Qiao; Du, Qin; Yu, Wenhua; Zheng, Yongke; Hu, Wei; Wang, Keyi; Chen, Fanghui; Xu, Yuanfu; Wang, Yi; Chen, Gao

doi:10.1016/j.cca.2018.08.036

Cited by 8 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior studies conducted in patients with sepsis described the potential role of biomarkers from the matrix metalloproteinase pathways in predicting sepsis outcomes ( 37 ). Higher plasma MMP-3 levels have been described in patients with sepsis as compared with patients with trauma and stroke ( 38 ).…”

Section: Discussionmentioning

confidence: 99%

“…We also determined that higher plasma TIMP-1/MMP-9 ratios are present in patients that develop shock, ARDS, and mortality as compared with sepsis patients who do not experience these complications. Prior studies conducted in patients with sepsis described the potential role of biomarkers from the matrix metalloproteinase pathways in predicting sepsis outcomes (37). Higher plasma MMP-3 levels have been described in patients with sepsis as compared with patients with trauma and stroke (38).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Elevated Plasma Levels of Matrix Metalloproteinase-3 and Tissue-Inhibitor of Matrix Metalloproteinases-1 Associate With Organ Dysfunction and Mortality in Sepsis

Jones

Reilly

Anderson

et al. 2021

Shock

View full text Add to dashboard Cite

Background: Matrix Metalloproteinases (MMP) respond to tissue damage during sepsis. Higher plasma concentrations of MMPs and the tissue-inhibitor of matrix metalloproteinases (TIMP) have been reported in sepsis compared with healthy controls. The objective of this study was to examine if plasma levels of MMP-3, MMP-9, and TIMP-1 associate with mortality and organ dysfunction during sepsis. Methods: We conducted a prospective cohort study of critically ill patients with sepsis adjudicated per Sepsis-3 criteria at a tertiary academic medical center. We measured plasma concentrations of MMP-3, MMP-9, and TIMP-1 on intensive care unit admission. We phenotyped the subjects for shock, acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), and mortality at 30 days. We used logistic regression to test the associations between the MMPs and TIMP-1 with shock, ARDS, AKI, and mortality. Results: Higher plasma TIMP-1 levels were associated with shock (odds ratio [OR] 1.51 per log increase [95% CI 1.25, 1.83]), ARDS (OR 1.24 [95% CI 1.05, 1.46]), AKI (OR 1.18 [95% CI 1.01, 1.38]), and mortality (OR 1.20 [95% CI 1.05, 1.46]. Higher plasma MMP-3 concentrations were associated with shock (OR 1.40 [95% CI 1.12, 1.75]) and mortality (OR 1.24 [95% CI 1.03, 1.48]) whereas MMP-9 levels were not associated with outcomes. Higher plasma TIMP-1 to MMP-3 ratios were associated with shock (OR 1.41 [95% CI 1.15, 1.72], P = 0.02). Conclusion: Elevated plasma concentrations of TIMP-1 associate with organ dysfunction and mortality in sepsis. Higher plasma levels of MMP-3 associate with shock and mortality. Plasma MMP and TIMP-1 may warrant further investigation as emerging sepsis theragnostic biomarkers.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Elevated Plasma Levels of Matrix Metalloproteinase-3 and Tissue-Inhibitor of Matrix Metalloproteinases-1 Associate With Organ Dysfunction and Mortality in Sepsis

Jones

Reilly

Anderson

et al. 2021

Shock

View full text Add to dashboard Cite

show abstract

“…Moreover, NSE and S100B have demonstrated a prognostic potential on early and long-term functional recovery after ischemic or hemorrhagic strokes and TBI [80,[84][85][86][87][88][92][93][94][95]. Likewise, elevated HMGB1 and sRAGE are predictors of poor prognosis after an IS [67,96] (Tables 1 and 2). Changes in HMGB1, S100B, and sRAGE concentrations during the hospital stay can also help to diagnose delayed injury such as proximal vasospasm and delayed cerebral ischemia after SAH [10,31,97] (Table 1).…”

Section: A Biomarker Approachmentioning

confidence: 97%

“…The protective effect of recombinant sRAGE in cerebral parenchyma has been recently depicted in an animal model of SAH [65]. Although the characteristics of sRAGE sound interesting for clinical objectives, it has been little studied in brain injuries, with inconsistent results for outcomes such as in acute IS [66], or aSAH [31,67]. These discrepencies in data may result from different types of sRAGE studied and timing of measurements.…”

Section: Damps Clearencementioning

confidence: 99%

DAMPs and RAGE Pathophysiology at the Acute Phase of Brain Injury: An Overview

Balança¹,

Desmurs²,

Grelier³

et al. 2021

IJMS

View full text Add to dashboard Cite

Early or primary injury due to brain aggression, such as mechanical trauma, hemorrhage or is-chemia, triggers the release of damage-associated molecular patterns (DAMPs) in the extracellular space. Some DAMPs, such as S100B, participate in the regulation of cell growth and survival but may also trigger cellular damage as their concentration increases in the extracellular space. When DAMPs bind to pattern-recognition receptors, such as the receptor of advanced glycation end-products (RAGE), they lead to non-infectious inflammation that will contribute to necrotic cell clearance but may also worsen brain injury. In this narrative review, we describe the role and ki-netics of DAMPs and RAGE at the acute phase of brain injury. We searched the MEDLINE database for “DAMPs” or “RAGE” or “S100B” and “traumatic brain injury” or “subarachnoid hemorrhage” or “stroke”. We selected original articles reporting data on acute brain injury pathophysiology, from which we describe DAMPs release and clearance upon acute brain injury, and the implication of RAGE in the development of brain injury. We will also discuss the clinical strategies that emerge from this overview in terms of biomarkers and therapeutic perspectives

show abstract

“…Recently, there is evidence that cRAGE may be the main form of circulating sRAGE after ischemic stroke (IS), and it may independently predict a poor prognosis. It has been shown that plasma sRAGE level is significantly increased in IS patients shortly after the event (<48 h after onset) and then decreased in 5–7 days ( Yang et al, 2018 ; Aida et al, 2021 ; Zhang et al, 2022 ).…”

Section: Specific Biomarkers For Disease Burden and Outcomes For Pati...mentioning

confidence: 99%

Biomarkers and the outcomes of ischemic stroke

Huang

Wang

Huang

et al. 2023

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Biomarkers are measurable substances that could be used as objective indicators for disease diagnosis, responses to treatments, and outcomes predictions. In this review, we summarized the data on a number of important biomarkers including glutamate, S100B, glial fibrillary acidic protein, receptor for advanced glycation end-products, intercellular adhesion molecule-1, von willebrand factor, matrix metalloproteinase-9, interleukin-6, tumor necrosis factor-a, activated protein C, copeptin, neuron-specific enolase, tau protein, gamma aminobutyric acid, blood glucose, endothelial progenitor cells, and circulating CD34-positive cells that could be potentially used to indicate the disease burden and/or predict clinical outcome of ischemic stroke. We examined the relationship between specific biomarkers and disease burden and outcomes and discussed the potential mechanisms underlying the relationship. The clinical significance and implications of these biomarkers were also discussed.

show abstract

Clinical relevance of cleaved RAGE plasma levels as a biomarker of disease severity and functional outcome in aneurysmal subarachnoid hemorrhage

Cited by 8 publications

References 42 publications

Elevated Plasma Levels of Matrix Metalloproteinase-3 and Tissue-Inhibitor of Matrix Metalloproteinases-1 Associate With Organ Dysfunction and Mortality in Sepsis

Elevated Plasma Levels of Matrix Metalloproteinase-3 and Tissue-Inhibitor of Matrix Metalloproteinases-1 Associate With Organ Dysfunction and Mortality in Sepsis

DAMPs and RAGE Pathophysiology at the Acute Phase of Brain Injury: An Overview

Biomarkers and the outcomes of ischemic stroke

Contact Info

Product

Resources

About